Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome
 

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications.

More...

Re: Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrom
 

Oh I am so excited to hear about this treatment!

My husband has porphyria, hemachromatosis and iron overload, among many other blood issues, leukemia, neutropenia, anemia.

Hearing about another treatment option, even if it is still in the future, makes me feel optimistic.

I just hate that clinical trials take so long :(

Re: Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrom
 

Oh I see it is already approved for treating Thalassemia.